March 18, 2020 10:43 AM EDT

Insilico inks another deal with Sino Biopharma unit; Ramaswamy's Datavant to invest in the "patient journey"

ENDPOINTS

→ Insilico — the well-connected AI drug discovery shop that has raised funds at the behest of Shanghai high-flyer WuXi AppTec, Singapore’s Temasek, Peter Diamandis, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Insilico inks another deal with Sino Biopharma unit; Ramaswamy's Datavant to invest in the "patient journey"

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

In­sil­i­co inks an­oth­er deal with Sino Bio­phar­ma unit; Ra­maswamy's Data­vant to in­vest in the "pa­tient jour­ney"

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Insilico inks another deal with Sino Biopharma unit; Ramaswamy's Datavant to invest in the "patient journey"

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?